Complete Guide to Magnesium Sulphate Pharmacokinetics
Overview
Magnesium Sulphate is a Anticonvulsant / Electrolyte used in the Obstetrics / Maternal Medicine therapeutic area. It is indicated for Pre-eclampsia and Eclampsia (seizure prophylaxis). Free interactive pharmacokinetic simulator for magnesium sulphate (MgSO₄) in pre-eclampsia and eclampsia. Based on Salinger et al. (2013) population PK model: 1-compartment, IV/IM dosing, body weight and serum creatinine covariates. Compare MAGPIE IV vs IM regimens, explore therapeutic window (2.0–3.5 mmol/L), and optimize seizure prophylaxis dosing.
Mechanism of Action
Magnesium Sulphate exerts its pharmacological effect by targeting NMDA receptor antagonist / CNS depressant. As a Anticonvulsant / Electrolyte, it modulates this target to achieve therapeutic efficacy in Pre-eclampsia and Eclampsia (seizure prophylaxis). Understanding the target engagement is critical for interpreting the pharmacokinetic-pharmacodynamic (PK/PD) relationship and optimizing dosing regimens.
Key Pharmacokinetic Parameters
The following parameters are derived from published PopPK — 1-Compartment, IV/IM models for Magnesium Sulphate:
| Parameter | Value |
|---|---|
| V | 15.6 L |
| BL | 0.85 mmol/L (endogenous baseline) |
| CL | 4.81 L/h |
| F1 | 86.2% (IM bioavailability) |
| KA | 0.317 h⁻¹ (IM absorption) |
| IIV CL | WT→V: V_i = V × (WT/55)^0.692 |
| t half | ~2.2 h |
| software | NONMEM 7, mixed-effects, proportional residual error |
| covariate effects | SCr→CL: CL_i = CL × (0.8/SCr)^1.48 |
Parameters represent typical population estimates from published literature. Individual values may vary.
Dosing & Administration
Magnesium Sulphate is administered via the IV, IM route. Intravenous administration provides 100% bioavailability and allows precise control of drug exposure. Infusion duration and rate can significantly impact peak concentrations.
Dosing recommendations should always follow approved prescribing information. The interactive simulator allows you to explore different dosing scenarios and their impact on drug exposure metrics such as AUC, Cmax, and Ctrough.
Clinical Considerations
In the Obstetrics / Maternal Medicine therapeutic area, for the treatment of Pre-eclampsia and Eclampsia (seizure prophylaxis), understanding the pharmacokinetics of Magnesium Sulphate is essential for dose optimization and therapeutic drug monitoring. Key clinical factors that may affect Magnesium Sulphate pharmacokinetics include:
- •Body weight and body composition
- •Renal and hepatic function
- •Drug-drug interactions and concomitant medications
- •Age, sex, and genetic polymorphisms
Interactive Magnesium Sulphate PK Simulator
Explore Magnesium Sulphate pharmacokinetics interactively. Adjust doses, dosing intervals, and patient covariates to visualize concentration-time profiles in real time.
Frequently Asked Questions
What is the half-life of Magnesium Sulphate?
The elimination half-life of Magnesium Sulphate depends on patient-specific factors. Based on published models, the typical half-life is approximately ~2.2 h.
How is Magnesium Sulphate administered?
Magnesium Sulphate is administered via the IV, IM route. It is indicated for Pre-eclampsia and Eclampsia (seizure prophylaxis). As a Anticonvulsant / Electrolyte, dosing regimens should follow approved prescribing information and clinical guidelines.
What are the key PK parameters of Magnesium Sulphate?
Key pharmacokinetic parameters for Magnesium Sulphate include clearance (CL), volume of distribution (Vd), and elimination half-life. See the PK Parameters section above for specific values from published models.
Can I simulate Magnesium Sulphate dosing scenarios for free?
Yes! PKPDBuilder offers a completely free, interactive Magnesium Sulphate PK simulator based on published pharmacometric models. No login required. Use it to explore different doses, dosing intervals, and patient covariates.
⚠️ Disclaimer
This guide is for research and educational purposes only. It is not intended for clinical decision-making or patient dosing. Parameters are derived from published literature and represent population estimates. Always consult approved prescribing information for clinical use.